Larimar Therapeutics: Analysts Predict Massive Upside Potential of Up to 430%
Reading Time: 3 minutes
Regulatory Breakthrough and Strategic Milestones Larimar Therapeutics (LRMR) (still listed under its former name Zafgen Inc. in the desk) is entering a groundbreaking phase in its corporate history, significantly driven by recent regulatory successes. At the end of February 2026, the US Food and Drug Administration (FDA) granted the coveted "Breakthrough Therapy" status for the main candidate Nomlabofusp for the treatment of Friedreich's ataxia. This milestone validates the immense potential of the protein replacement therapy and confirms the...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
